Results 161 to 170 of about 10,191,051 (291)

LTB‐TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma

British Journal of Haematology, EarlyView.
LTB‐TREAT is a validated international prognostic model that identifies three groups of patients with distinct rates of time to treatment (TTT) in low tumour burden follicular lymphoma. The low‐risk group has a prolonged TTT with WW. The high‐risk group has early progression in whom treatment at diagnosis can be considered. Summary Watchful waiting (WW)
Luani Barge, Lachlan Webb, Anita Pelecanos, Niamh Waters, Ross Salvaris, Sam Lai, Tessa Potezny, Helen Cashman, Caitlyn Nguyen‐Ngo, Denise Lee, Costas K. Yannakou, Nada Hamad, Adrien Chauchet, Sylvain Choquet, Cédric Rossi, Adélie Herbin, Lukshe Kanagaratnam, Cyrielle Rodier, Constantine S. Tam, Abir Bhattacharyya, Chan Y. Cheah, Eliza A. Hawkes, Kirk Morris, Eric Durot, Joshua Tobin, Greg Hapgood   +25 more
wiley   +1 more source

Dural Follicular Non-Hodgkin Lymphoma Mimicking a Chronic Subdural Hematoma: A Case Report and Literature Review. [PDF]

Cureus
Arellanes-Chavez CA, Ramos Mertinez E.
europepmc   +1 more source

Practices of Antifungal Prophylaxis Among Italian Pediatric Oncology-Hematology Centers. [PDF]

EJHaem
Colli M, Grasso A, Spadea M, Compagno F, Chiusaroli L, Muggeo P, Pancaldi A, Mura R, Onofrillo D, De Santis R, Mongelli B, Barone A, Rinieri S, Coccia P, Ricci E, Faraci M, D'Amico MR, Galaverna F, Gasperini P, Brescia L, Colombini A, Masetti R, Baccelli F, Cesaro S.   +23 more
europepmc   +1 more source

Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly (HALO trial)

British Journal of Haematology, EarlyView.
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini, Simonetta Viviani, Davide Rapezzi, Caterina Patti, Pierre Feugier, Alessandro Rambaldi, Fontanet Bijou, Anna Borra, Cécile Borel, Tanguy Pace‐Loscos, Renaud Schiappa, Stephane Chauvie, Colin Debaigt, Anna Guidetti, Olivier Humbert, Jean‐Marc Schiano De Colella   +15 more
wiley   +1 more source

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

Primary ocular-adnexal non-Hodgkin Lymphoma in a Peruvian cohort: An 18-year experience. [PDF]

PLoS One
Luque-Benavides R, Cruz Ku G, Valcarcel B, Garcia A, Davila Galecio F, Luque A, Lujan Peche MG, Cruzado Sanchez D, Enriquez-Vera D.   +8 more
europepmc   +1 more source

Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests

British Journal of Haematology, EarlyView.
Summary Haematological malignancies are rare in primary care and are hard to predict. Existing prediction models often require a specific working diagnosis and are based on extensive clinical information, access to which may be limited at initial work‐up in primary care.
Mathilde Egelund Christensen, Michael Charles Sachs, William Grant Dunn, Gustav Jonzon, Margit Kriegbaum, Bent Struer Lind, Jan Samuelsson, Kirsten Groenbaek, George Vassiliou, Christen Lykkegaard Andersen   +9 more
wiley   +1 more source

Clinical spectrum and survival outcomes of malignancies in pediatric patients with inborn errors of immunity. [PDF]

Front Immunol
Deveci Demirbas N, Haskologlu ZS, Baylan T, Islamoglu C, Kostel Bal S, Baskin K, Gul B, Aytekin C, Kaygusuz G, Kendirli T, Fitoz S, Incesoy Ozdemir S, Dincaslan H, Kuzu I, Tacyildiz N, Unal E, Dogu F, Ikinciogullari A.   +17 more
europepmc   +1 more source

Efficacy and safety of high doses of eltrombopag for treating adult immune thrombocytopenia: Results from a multicentre retrospective cohort study

British Journal of Haematology, EarlyView.
Salomé Dahan, Stéphanie Guillet, Olivier Fain, Delphine Gobert, Stéphane Cheze, Florent Broca, Bertrand Godeau, Marc Michel   +7 more
wiley   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source